nach oben

The European Journal of Health Economics

Erschienen in:

01.02.2012 | Original Paper

The convergence of health care financing structures: empirical evidence from OECD-countries

verfasst von: Andrea M. Leiter, Engelbert Theurl

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The convergence/divergence of health care systems between countries is an interesting facet of the health care system research from a macroeconomic perspective. In this paper, we concentrate on an important dimension of every health care system, namely the convergence/divergence of health care financing (HCF). Based on data from 22 OECD countries in the time period 1970–2005, we use the public financing ratio (public financing in % of total HCF) and per capita public HCF as indicators for convergence. By applying different concepts of convergence, we find that HCF is converging. This conclusion also holds when we look at smaller subgroups of countries and shorter time periods. However, we find evidence that countries do not move towards a common mean and that the rate of convergence is decreasing over time.

Nur mit Berechtigung zugänglich

Some studies focus on the outcome indicator health status. For example, Mayer-Foulkes [26] asks whether there are convergence clubs in cross-country life expectancy dynamics.

For the discussion of testing convergence using cross-section or time series data and methods, see Bernard and Durlauf [4]. For the closely related problem of stationarity of health care expenditures and their determinants, see for example Hansen and King [18], McCoskey and Selden [27], Gerdtham and Löthgren [12], Okunade and Karakus [37], MacDonald and Hopkins [25], Dreger and Reimers [11].

Private health insurance can offer primary, duplicate, complementary and supplementary coverage. For a detailed discussion of these different functions, see OECD [36].

Disaggregated information on the different sources of HCF focused on the collecting stage is not available yet. Hence, health expenditures of public institutions (consisting of central government, provinces/states, municipalities/local governments, social security funds and selected private non-profit institutions) are taken as an indicator for public financing.

Overall, time invariant, country-specific characteristics and differences in the countries’ health care systems that cannot be addressed specifically are accounted for by the specific estimation method (biased corrected LSDV estimator) applied.

http://www.oecd.org/document/21/0,3343,en_2649_33927_40917154_1_1_1_1,00.html

Only for data on union density and total tax revenues in Iceland, we cannot justify this replacement of missing entries which results in a loss of 13 observations.

The latter concepts were developed within the framework of neoclassical growth models to explain the convergence in aggregate output (see [3] for convergence in income per capita) and assume the existence of a steady-state in economic development.

Note that our dependent variable refers to its quantity in period t (instead of its growth). If we subtracted 1 from the parameter b, we would get the corresponding coefficient if the growth rate was the dependent variable. The speed of β-convergence can be calculated from the regression coefficient b on the initial level y ₀. For example, for the specification at hand, the speed of convergence equals $-\frac{ln(T b)}{T}$.

One may doubt the exogeneity of the explanatory variables included. Although public HCF may shape the regressors used, such influences do not occur contemporaneously. Rather, it is adequate to assume that the effects of public HCF on the regressors occur with some time lags meaning that today’s HCF influences tomorrow’s insurance coverage, proportion of elderly, GDP, … but not today’s levels.

We determine the number of lags to be included based on the Schwartz Bayesian information criterion and the Akaike information criterion.

If b = 1, the series follows a random walk.

These values were calculated by multiplying public with the real health expenditures per capita that range from 174 to 5,616 US$ with a mean of 1,670 US$.

NHS countries are Denmark, Finland, Ireland, Iceland, Italy, Norway, Portugal, Sweden, Spain and the United Kingdom. Austria, Belgium, Germany, France, Luxembourg and the Netherlands represent the group of SHI countries. Australia, Canada, Japan, New Zealand, Switzerland and the United States together form the group ‘Others’ as they can neither be classified as NHS nor as SHI countries (Switzerland, USA) or do not belong to Europe.

In order to improve clarity, we forgo plotting public for the third group. The corresponding values are lower at each point in time. The minimum (maximum) is 63.2% (69.3%) in 1971 (1984). The line in Fig. 3 referring to the total sample includes these values. This explains why the curve picturing the total sample always runs below the curves for the two other subsamples.

As before, we do not plot the values for the other countries for clarity reasons but their values are included in the plot representing the total sample.

For the panel specification, the rate of convergence is given by β = − (ln b).

We classify those countries as old NHS countries which were already NHS-systems at the beginning of the observation period (Denmark, Great Britain, Finland, Iceland, Ireland, Norway, Sweden). Countries that changed to a NHS-system during the past 36 years are defined as new NHS countries (Italy in 1978, Portugal in 1979, Spain in 1987).

Alcalde-Unzu J., Ezcurra R., Pascual P.: Cross-country disparities in health-care expenditure: a factor decomposition. Health Econ. 18, 479–485 (2009)PubMedCrossRef

Aldridge, S.C., Sundarapandiyan, S.: The convergence model in health care reform: experience from Singapore, the United Kingdom and the United States. Asian J. Public Admin. 17, 60–104 (1995)

Barro, R.J., Sala-i Martin, X.: Convergence. J. Politic. Econ. 100, 223–251 (1992)CrossRef

Bernard, A.B., Durlauf, S.N.: Interpreting tests of the convergence hypothesis, technical working paper series 159, NBER (1994)

Bruno, G.S.F.: Estimation and inference in dynamic unbalanced panel data models with a small number of individuals, working paper 165, Universita Bocconi-CESPRI (2005)

Busse, R., Schreyögg, J., Gericke, C.: Analyzing changes in health financing arrangements in high-income countries—a comprehensive framework approach, health, nutrition and population (HNP) discussion paper of the World Bank’s Human Development Network, World Bank. http://www.worldbank.org/hnppublications (2007)

Clemente, J., Marcuello, C., Montañes, A., Pueyo, F.: On the international stability of health care expenditure functions: are government and private functions similar? J. Health Econ. 23, 589–613 (2004)PubMedCrossRef

Cohen, R.A., Makuc, D.M., Bernstein, A.B., Bilheimer, L.T., Powel-Griner, E.: Health insurance coverage trends: estimates from the national health interview survey. Natl. Health Stat. Rep. 17, 1–28 (2009)

Comas Herrera, A. Is there a convergence in the health expenditures of the EU member states. In: Mossialos E., Le Grand J. (eds) Health Care and Cost Containment in the European Union. Ashgate, Aldershot, pp. 197–218 (1999)

10.

Corrado, L., Londoño, B.D.A., Mennini, F.S., Trovato, G.: The welfare states in a United Europe. Eur. Politic. Econ. Rev. 1, 40–55 (2003)

11.

Dreger, C., Reimers, H.-E.: Health care expenditures in OECD countries: a panel root and cointegration analysis. Int. J. Appl. Econ. Quant. Stud. 2, 5–20 (2005)

12.

Gerdtham, U.-G., Löthgren, M.: On stationarity and conintegration of international health expenditure and GDP. J. Health Econ. 19, 461–475 (2000)PubMedCrossRef

13.

Glied, S.A.: Health care financing, efficiency, and equity, working paper No. 13881, NBER. http://www.nber.org/papers/w13881 (2008)

14.

Glied, S.A.: Universal public health insurance and private coverage: externalities in health care consumption, working paper No. 13885, NBER. http://www.nber.org/paperss/w13885 (2008)

15.

Globerman, S., Hodges, H., Vining, A.: Canadian and US health care systems performance and governance: elements of convergence, technical report, EconWPA. http://www.129.3.20.41/eps/pe/papers/0404/0404003.pdf (2001)

16.

Globerman, S., Vining, A.: A policy perspective on ‘mixed’ health care financial systems of business and economics. J. Risk Insur. 65, 57–80 (1998)CrossRef

17.

Gouveia, M.: The public sector and health care. Int. Tax Public Financ. 3, 329–349 (1996)CrossRef

18.

Hansen, P., King, A.: The determinants of health care expenditure: a cointegration approach. J. Health Econ. 15, 127–137 (1996)PubMedCrossRef

19.

Hitiris, T., Nixon, J.: Convergence of health care expenditure in the EU countries. Appl. Econ. Lett. 8, 223–228 (2001)CrossRef

20.

Hurley, J.: An overview of the normative economics of the health care sector. In: Culyer A.J., Newhouse J.P. (eds) Handbook of Health Economics, vol. 1A. Elsevier, Amsterdam, pp. 55–118 (2000)

21.

Kerem, K., Puss, T., Maldre, R.: Health and convergence of health care expenditure in EU. Int. Business Econ. Res. J. 2, 29–43 (2008)

22.

Kim, T.-K., Zurlo, K.: How does economic globalisation affect the welfare state? focusing on the mediating effect of welfare regimes. Int. J. Soc. Welf. 17, 1–12 (2008)CrossRef

23.

Kiviet, J.F.: On bias, inconsistency, and efficiency of various estimators in dynamic panel data models. J. Econ. 68, 53–78 (1995)

24.

Levin, A., Lin, C.-F., Chu Chia-Shang, J.: Unit root tests in panel data: asymptotic and finite sample properties. J. Econ. 108, 1–24 (2002)

25.

MacDonald G., Hopkins S.: Unit root properties of OECD health care expenditure and GDP data. Health Econ. 11, 371–376 (2002)PubMedCrossRef

26.

Mayer-Foulkes, D.: Convergence clubs in cross-country life expectancy dynamics, discussion paper No. 2001/124, World Institute for Development Economics Research (2001)

27.

McCoskey, S., Selden, T.: Health care expenditures and GDP: panel data unit root test results. J. Health Econ. 17, 369–376 (1998)PubMedCrossRef

28.

Montero-Granados, R., De Dios Jimenez, J., Martin, J.: Decentralisation and convergence in health among the provinces of Spain. Soc. Sci. Med. 64, 1253–1264 (2007)PubMedCrossRef

29.

Narayan P.K.: Do health expenditures ‘catch-up’?. Evidence from OECD countries. Health Econ. 16, 993–1008 (2007)PubMedCrossRef

30.

Narayan, P.K., Narayan, S.: The role of permanent and transitory shocks in explaining international health expenditures. Health Econ. 17, 1171–1186 (2008)PubMedCrossRef

31.

Nerlove, M.: Further evidence on the estimation of dynamic economic relations from a time series of cross-sections. Econometrica 39, 359–387 (1971)CrossRef

32.

Nickell, S.: Biases in dynamic models with fixed effects. Econometrica 49, 1417–1426 (1981)CrossRef

33.

Nixon, J.: Convergence analysis of health care expenditure using two approaches, Discussion Papers in Economics No. 99/3, University of York (1999)

34.

Nixon, J.: Convergence of health care spending and health outcomes in the European Union, 1960-95, Discussion Paper Series No. 183, Centre for Health Economics (2000)

35.

OECD: A System of health accounts, Paris (2000)

36.

OECD: Private health insurance in OECD countries, Paris (2004)

37.

Okunade, A., Karakus, M.C.: Unit root and cointegration tests: time series versus panel estimates for international health expenditure models. Appl. Econ. 33, 1131–1137 (2001)

38.

Okunade, A., Murthy, V.: Technology as a ‘major driver’ of health care costs: a cointegration analysis of the Newhouse conjecture. J. Health Econ. 21, 147–159 (2002)CrossRef

39.

Okunade A., Suraratdecha C.: The pervasiveness of pharmaceutical expenditure inertia in the OECD countries. Soc. Sci. Med. 63, 225–238 (2006)PubMedCrossRef

40.

Pierson, P.: Increasing returns, path dependence, and the study of politics. Am. Politic. Sci. Rev. 94, 251–267 (2000).CrossRef

41.

Propper, C., Green, K.: A larger role for the private sector in health care? a review of arguments, working paper series no. 99/009, Centre for Market and Public Organisation (CMPO) (1999)

42.

Saltman, R.B.: Convergence versus social embeddedness. Eur. J. Public Health 7, 449–453 (1997)CrossRef

43.

Sanz I., Velázquez, F.J.: The evolution and convergence of the government expenditure composition in the OECD countries. Public Choice 119, 61–72 (2004)CrossRef

44.

van Doorslaer, E., Koolman, X., Jones, A.: Explaining income-realted inequalities in doctors utilisation in Europe. Health Econ. 13, 629–647 (2004)PubMedCrossRef

45.

Wagstaff, A., van Doorslaer.: Equity in health care finance and delivery. In: Culyer A., Newhouse J. (eds) Handbook of Health Economics, vol. 2. Elsevier, Amsterdam, pp. 1803–1862 (2000)

46.

Wang, Z.: The convergence of health care expenditure in the US States. Health Econ. 18, 55–70 (2009)PubMedCrossRef

47.

Wendt, C., Grimmeisen, S., Rothgang, H.: Convergence or divergence of OECD health care systems?. In: Cantillon B., Marx I. (eds) International Cooperation in Social Security. Antwerpen, Oxford, pp. 15–45 (2005)

48.

Wolf, H.: Globalization and the convergence of social expenditure in the European union, occasional paper series, GW Center of the Study of Globalization (2002)

49.

Wooldridge, J.M.: Econometric Analysis of Cross Section and Panel Data. Cambridge and London: MIT-Press(2002)

Titel: The convergence of health care financing structures: empirical evidence from OECD-countries
verfasst von: Andrea M. Leiter
Engelbert Theurl
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 1/2012
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-010-0265-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

The impact of presumed consent laws and institutions on deceased organ donation

The cost of multiple sclerosis in Norway

Future costs in cost-effectiveness analysis: an empirical assessment

Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications

Spillover effects of supplementary on basic health insurance: evidence from the Netherlands